Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ionis Pharmaceuticals (IONS)
NASDAQ:IONS
Holding IONS?
Track your performance easily
IONS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$35.95 - $54.44
Previous Close$46.92
Volume773.51K
Average Volume (3M)1.26M
Market Cap
$6.86B
Enterprise Value$4.99B
Total Cash (Recent Filing)$2.08B
Total Debt (Recent Filing)$210.86M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Oct 31, 2024EPS Estimate
-$1.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.53
Shares Outstanding146,211,091
10 Day Avg. Volume763,702
30 Day Avg. Volume1,261,089
Standard Deviation0.09
R-Squared0.05
Alpha-0.00533
Financial Highlights & Ratios
Price to Book (P/B)26.36
Price to Sales (P/S)8.54
Price to Cash Flow (P/CF)-14.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.14
Enterprise Value/Gross Profit6.41
Enterprise Value/Ebitda-18.14
Forecast
1Y Price Target
$60.40Price Target Upside28.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
Ionis Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
EarningsRevenue of $225mm beat consensus estimates, primarily driven by R&D revenue.
Pipeline ProgressThe company's ongoing transition to increased focus on commercialization of wholly owned assets.
Regulatory ApprovalQalsody received European Commission approval, triggering a milestone payment to IONS and future royalties.
Bears Say
Drug DiscontinuationIONS announced discontinuation of IONIS-FB-LRx for geographic atrophy (GA) and ION541 for amyotrophic lateral sclerosis (ALS) as both assets demonstrated insufficient efficacy to advance into Phase 3.
Investor UpdatesOverall, the 2Q call offered no meaningful updates, which isn’t surprising given investor focus remains on the mid/late-stage pipeline.
Pipeline ManagementIONS has advanced too many promising drugs (25 clinical programs) that can reduce focus, consume resources, and increase ambiguity around each opportunity.
---
Ownership Overview
2.97% Insiders
39.02% Mutual Funds
51.50% Other Institutional Investors
6.51% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IONS FAQ
What was Ionis Pharmaceuticals’s price range in the past 12 months?
Ionis Pharmaceuticals lowest stock price was $35.95 and its highest was $54.44 in the past 12 months.
What is Ionis Pharmaceuticals’s market cap?
Currently, no data Available
When is Ionis Pharmaceuticals’s upcoming earnings report date?
Ionis Pharmaceuticals’s upcoming earnings report date is Oct 31, 2024 which is in 68 days.
How were Ionis Pharmaceuticals’s earnings last quarter?
Ionis Pharmaceuticals released its earnings results on Aug 01, 2024. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.925 by $0.475.
Is Ionis Pharmaceuticals overvalued?
According to Wall Street analysts Ionis Pharmaceuticals’s price is currently Undervalued.
Does Ionis Pharmaceuticals pay dividends?
Ionis Pharmaceuticals does not currently pay dividends.
What is Ionis Pharmaceuticals’s EPS estimate?
Ionis Pharmaceuticals’s EPS estimate is -$1.12.
How many shares outstanding does Ionis Pharmaceuticals have?
Ionis Pharmaceuticals has 146,211,090 shares outstanding.
What happened to Ionis Pharmaceuticals’s price movement after its last earnings report?
Ionis Pharmaceuticals reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.925. Following the earnings report the stock price went up 3.761%.
Which hedge fund is a major shareholder of Ionis Pharmaceuticals?
Among the largest hedge funds holding Ionis Pharmaceuticals’s share is Tweedy Browne CO LLC. It holds Ionis Pharmaceuticals’s shares valued at 165M.
---
Ionis Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$60.40 (28.73% Upside)
$60.40 (28.73% Upside)
Blogger Sentiment
Bullish
IONS Sentiment 85%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 799.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $644.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.12%
12-Months-Change
Fundamentals
Return on Equity
-105.63%
Trailing 12-Months
Asset Growth
-9.42%
Trailing 12-Months
Company Description
Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.
---
IONS Company Deck
---
IONS Earnings Call
Q2 2024
0:00 / 0:00
---
IONS Revenue Breakdown
60.82% R&D
39.18% Commercial
---
IONS Stock 12 Month Forecast
Average Price Target
$60.40
▲(28.73% Upside)
Technical Analysis
Best Analysts Covering IONS
1 Year
1 Year Success Rate
12/15 ratings generated profit
1 Year Average Return
+17.35%
initiated a buy rating 11 months ago
Copying Gary Nachman's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +17.35% per trade.
---